The use of Thalidomide in patients with ALS who have disease progression.
Phase II open labeled trial testing the efficacy of thalidomide for ALS in the setting of
- Clinically proven ALS
- Disease duration less than or equal to 5 years
- ALSFRS-R score equal to or greater then 30
- Patients with known deep venous thrombosis or hyper coagulable state will be excluded
- Patients with FVC less than 80%